000 02165na a2200313 4500
999 _c8070
_d8070
003 PC8070
005 20181107143116.0
008 130622s2013 xxx||||| |||| 00| 0 eng d
040 _cH12O
041 _aeng
100 _aPraga Terente, Manuel
_91488
_eNefrología
245 0 0 _aEffect of Dual Blockade of the Renin-Angiotensin System on the Progression of Type 2 Diabetic Nephropathy: A Randomized Trial.
_h[artículo]
260 _bAmerican Journal of Kidney Diseases,
_c2013
300 _a61(2):211-8.
500 _aFormato Vancouver: Fernández Juárez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M et al. PRONEDI Study Group. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. Am J Kidney Dis. 2013 Feb;61(2):211-8.
501 _aPMID: 22939518
504 _aContiene 28 referencias
520 _aBackground: Blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers has been shown to lessen the rate of decrease in glomerular filtration rate in patients with diabetic nephropathy. Study Design: A multicenter open-label randomized controlled trial to compare the efficacy of combining the angiotensin-converting enzyme inhibitor lisinopril and the angiotensin II receptor blocker irbesartan with that of each drug in monotherapy (at both high and equipotent doses) in slowing the progression of type 2 diabetic nephropathy. Setting & Population: 133 patients with type 2 diabetic nephropathy (age, 66 +/- 8 years; 76% men) from 17 centers in Spain. Intervention: Patients were randomly assigned (1:1:2) to lisinopril (n = 35), irbesartan (n = 28), or the combination of both (n = 70). Outcomes: The primary composite outcome was a >50% increase in baseline serum creatinine level, end-stage renal disease, or death. Results: Baseline values for mean estimated glomerular filtration rate and blood pressure were 49 +/- 21 mL/min/1.73 m(2) and 153 +/- 19/81 +/-
710 _986
_aServicio de Nefrología
856 _uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/8/pc8070.pdf
_ySolicitar documento
942 _n0
_2ddc
_cART